Bristol-Myers Squibb (Switzerland) - Academic Profile

Publications

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Noopur Raje , Jesús G. Berdeja , Yi Lin +20 more

We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented. (F...

2019 New England Journal of Medicine 1641 citations

NCCN Guidelines Insights: Colon Cancer, Version 2.2018

Steven R. Hunt , Ahmed Kamel , Natalie Kirilcuk +33 more

The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, management of r...

2018 Journal of the National Comprehensive... 979 citations

Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma

Nathalie A. Johnson , Pier Luigi Zinzani , Eva Domingo‐Doménech +17 more

Overall, the efficacy data from CheckMate 436 do not support the use of nivolumab plus BV for the treatment of R/R DLBCL.

2025 Future Oncology 0 citations

Affiliated Researchers

Institution Info

Type: company
Country: CH
Publications: 3
Citations: 2,620

External Links

Identifiers

ROR: https://ror.org/02xqc6638

Publications

Affiliated Researchers

Institution Info

External Links

Identifiers

Research Output Over Time